{"id":390178,"date":"2020-08-19T00:00:00","date_gmt":"2020-08-19T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algomd0023-2020-biopharma-type-2-diabetes-treatment-algorithms-claims-data-analysis-us-2020\/"},"modified":"2026-04-18T23:23:07","modified_gmt":"2026-04-18T23:23:07","slug":"algomd0023-2020-biopharma-type-2-diabetes-treatment-algorithms-claims-data-analysis-us-2020","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algomd0023-2020-biopharma-type-2-diabetes-treatment-algorithms-claims-data-analysis-us-2020\/","title":{"rendered":"Type 2 Diabetes | Treatment Algorithms | Claims Data Analysis | US | 2020"},"content":{"rendered":"<p>Metformin and sulfonylureas are the most heavily prescribed type 2 diabetes drugs and dominate the early lines of therapy, before disease progression requires insulin replacement. The emergence of more-effective, safer, and\/or better-tolerated therapies, such as the sodium glucose contransporter-2 (SLGT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists, have provided physicians with a broad array of therapeutic options. Moreover, with better understanding of type 2 diabetes and its complications, individualization of treatment is becoming more common. Numerous branded agents from both established and recently emergent classes are now jostling for position in the treatment paradigm.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What patient shares do key therapies and brands garner by line of therapy in newly diagnosed type 2 diabetes patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed type 2 diabetes patients?<\/li>\n<li>How have Steglatro, Ozempic, Rybelsus, and Tresiba been integrated into the treatment algorithm, and what are their sources of business?<\/li>\n<li>What percentage of type 2 diabetes patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?<\/li>\n<li>What percentage of type 2 diabetes patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated patients?<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-390178","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-type-1-diabetes","biopharma-therapy-areas-type-2-diabetes","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-942"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390178","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390178\/revisions"}],"predecessor-version":[{"id":393303,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390178\/revisions\/393303"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390178"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}